medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2020, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2020; 18 (1)

Pityriasis rubra pilaris: a review

Mancilla-Gudiel PM, Arenas R

Language: Spanish
References: 28
Page: 53-61
PDF size: 307.08 Kb.


ABSTRACT

Pityriasis rubra pilaris (PRP) is a rare disease of unknown etiology that occurs in the first, second and sixth decades of life. The clinical characteristics are very variable, but in general, it presents erythematous follicular papules and salmon squamous plaques that come together and leave patches of unaffected skin, which is a very distinctive feature of this disease; PRP is often associated with palmoplantar keratoderma. Dermoscopy supports the clinical evaluation and makes possible the distinction with the most common differential diagnosis, psoriasis. The diagnosis is clinical and is confirmed by histopathological findings like the “chessboard” pattern, typical of PRP, although it is not pathognomonic. Topical treatments are the basis of management systemic medications and should be added in severe cases. Systemic retinoids are considered first-line treatment, methotrexate as second-line, and due to their high costs and still limited clinical evidence, biological agents have been left as the third line of treatment. To date, all the available medications used to treat this disease is based on case reports or series of published clinical cases.


REFERENCES

  1. Arenas R, Dermatología. Atlas, diagnóstico y tratamiento, 7ª ed., México, McGraw-Hill Interamericana, 2019.

  2. Kubanov A y Gallyamova Y, Diagnosis and treatment of pityriasis rubra pilaris, Serb J Dermatovenereol 2014; 6(4):167-73.

  3. Lallas A, Apalla Z, Karteridou A y Lefaki I, Dermoscopy for discriminating between pityriasis rubra pilaris and psoriasis, J Dermatol Case Rep 2013; 1:20-2.

  4. Ross NA, Chung HJ, Li Q, Andrews JP, Keller MS y Uitto J, Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients, jama Dermatol 2016; 152(6):670-5.

  5. Roenneberg S y Biedermann T, Pityriasis rubra pilaris: algorithms for diagnosis and treatment, J Eur Acad Dermatol Venereol 2017; 2018(32):889-98.

  6. Kromer C, Sabat R, Celis D y Mössner R, Systemic therapies of pityriasis rubra pilaris: a systematic review, J Dtsch Dermatol Ges 2018; 17(3):243-59.

  7. Stephen CPT, Stacey K, Novek SJ, Craig LTC y Maddox L, Pityriasis rubra pilaris in a 3-year-old male, Mil Med 2016; 181(3):298-301.

  8. Lora V, De Felice C, Cota C, Graceffa D, Morrone A y Bonifati C, A case of juvenile pitiriasis rubra pilaris tipe iii successfully treated with etanercept, Dermatol Ther 2017; 31(1):e12577.

  9. Carvajal C, Acosta A y Álvarez M, Pitiriasis rubra pilaris atípica en pediatría: a propósito de un caso, Arch Pediatr Urug 2017; 88(5):279-83.

  10. Moretta G, De Luca EV y Di Stefani A, Management of refractory pityriasis rubra pilaris: challenges and solutions, Clin Cosmet Investig Dermatol 2017; 10:451-7.

  11. Curi M, Del Puerto C y Vera C, Pitiriasis rubra pilaris, Rev Chilena Dermatol 2014; 30(2):189-96.

  12. Napolitano M, Abeni D y Didona B, Biologics for pityriasis rubra pilaris treatment: a review of the literature, J Am Acad Dermatol 2018; 79(2):353-9.

  13. Kelly A y Lally A, Pityriasis rubra pilaris: a rare inflammatory dermatosis, bmj Case Rep 2018; 1-2.

  14. Al-Hage J, Akel R, Kurban M y Abbas O, Plasmacytoid dendritic cells in pityriasis rubra pilaris, Ann Dermatol 2019; 31(1):87-90.

  15. Kaminetsky JR, Feit EJ y Ungar JP, Treatment of pityriasis rubra pilaris with adalimumab: a case report, J Cutan Med 2018; 2(5):336-9.

  16. MacGillivray ME y Fiorillo L, Recurrent pityriasis rubra pilaris: a case report, J Cutan Med Surg 2018; 22(6):624-6.

  17. Alazemi A, Balakirski G, Al Shehhi F, Lehmann S, Tenbrock K y Megahed M, Juvenile pityriasis rubra pilaris: successful treatment with methotrexate, Clin Exp Dermatol 2017; 43:110-12.

  18. Yun CH, Kim JS, Ryu HR, Kim JH, Baek JO, Lee JR et. al., Circumscribed juvenile pitiriasis rubra pilaris responsive to alitretinoin, Dermatol Ther 2016; 29: 81-3.

  19. Bar-Ilan E, Gat A, Sprecher E y Zeeli T, Paraneoplastic pityriasis rubra pilaris: case report and literature review, Clin Exp Dermatol 2016; 42:54-7.

  20. Jha AK, Lallas A, Sonthalia S, Jhakar D, Udayan UK y Chaudhary RKP, Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy, Dermatol Pract Concept 2018; 8(4):299-302.

  21. Balevi A, Türkmen I, Uc,ar Y y Özdemir M, Dermoscopy may be a valuable additional tool in diagnosis of pityriasis rubra pilaris: letter to the editor, Turkiye Klinikleri J Dermatol 2016; 26(1):69-70.

  22. López-Gómez A, Vera-Casaño Á, Gómez-Moyano E, Salas-García T, Dorado-Fernández M, Hernández-Gil-Sánchez J et al., Dermoscopy of circumscribed juvenil pityriasis rubra pilaris, J Am Acad Dermatol 2015; 72:S58-9.

  23. Abdel-Azim NE, Ismail SA y Fathy E, Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy, Arch Dermatol Res 2017; 309(4):311-4.

  24. Nair PA y Sheth N, Dermoscopy of juvenile circumscribed pityriasis rubra pilaris, Indian Dermatol Online J 2018; 9(6):474-6.

  25. Kumar S, Vinay K y Radotra BD, Dermoscopy of erythrodermic pityriasis rubra pilaris, Indian Dermatol Online J 2019; 10(4):500-1.

  26. Schuster D, Pfister-Wartha A, Bruckner-Tuderman L y Schempp CM, Succesful treatment of refractory pityriasis rubra pilaris with secukinumab, jama Dermatol 2016; 152(11):1278-80.

  27. Koch L, Schöffl C, Aberer W y Massone C, Methotrexate treatment for pityriasis rubra pilaris: a case series and literature review, Acta Derm Venereol 2018; 98:501-5.

  28. Matsuda T, Yamazaki F, Ueda-Hayakawa I, Kambe N y Okamoto H, Case of pityriasis rubra pilaris progressed to generalized erythroderma following blockade of interleukin-17A, but improved after blockade of interleukin-12/23 p40, J Dermatol 2019; 46:70-2.




2020     |     www.medigraphic.com